Kymera Therapeutics (KYMR)

• Market cap: $2.38B
• 1 day: -1.63%
• 5 days: -0.49%
• 1 month: -15.77%
• 3 months: -15.40%
• 6 months: -24.18%
• Year to date: -9.98%
• 1 year: -4.81%
• 5 years: 10.67%
• 10 years: 10.67%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Employees: 184

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

326% more call options, than puts

Call options by funds: $3M | Put options by funds: $704K

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

1.48% more ownership

Funds ownership: 108.38% [Q3] → 109.86% (+1.48%) [Q4]

2% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 59

1% more funds holding

Funds holding: 175 [Q3] → 176 (+1) [Q4]

12% less capital invested

Capital invested by funds: $3.27B [Q3] → $2.86B (-$409M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $55 49% upside
• Avg. target: $58 59% upside
• High target: $60 63% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Stephens & Co. Sudan Loganathan 26% 1-year accuracy 6 / 23 met price target	63% upside $60	Overweight Reiterated	21 Jan 2025
Leerink Partners Faisal Khurshid 18% 1-year accuracy 2 / 11 met price target	63% upside $60	Outperform Maintained	27 Dec 2024
BTIG Jeet Mukherjee 0% 1-year accuracy 0 / 2 met price target	63% upside $60	Buy Initiated	10 Dec 2024
BMO Capital Etzer Darout 18% 1-year accuracy 7 / 39 met price target	49% upside $55	Market Perform Initiated	6 Dec 2024
Wells Fargo Derek Archila 49% 1-year accuracy 17 / 35 met price target	55% upside $57	Overweight Upgraded	2 Dec 2024